Skip to content

Earnings yield at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
5.9%+1.6pp
Eli Lilly logo
Eli LillyLLY
3.1%+1.6pp
Johnson & Johnson logo
Johnson & JohnsonJNJ
3.6%-1.9pp
Amgen logo
AmgenAMGN
4.1%+0.6pp
AbbVie logo
AbbVieABBV
0.9%-0.2pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-4.6%-1.8pp

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$4.36B+533%
Enterprise value$4.32B+690%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Calculated from Oruka Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s earnings yield?
Oruka Therapeutics, Inc. (ORKA) reported earnings yield of -4.8% in Q1 2026.
How has Oruka Therapeutics, Inc.'s earnings yield changed year-over-year?
Oruka Therapeutics, Inc.'s earnings yield increased by 88.2% year-over-year, from -40.5% to -4.8%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.